Brief: United Therapeutics Corporation Concludes Enrollment Of The Advance Outcomes Study Of Ralinepag
23/06/2025 12:06
June 23 (Reuters) - United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS CORPORATION CONCLUDES ENROLLMENT OF THE ADVANCE OUTCOMES STUDY OF RALINEPAG FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION UNITED THERAPEUTICS CORP - ADVANCE OUTCOMES WILL CONTINUE TO ACCRUE CLINICAL WORSENING EVENTS THROUGH END OF 2025 UNITED THERAPEUTICS CORP - ADVANCE OUTCOMES TOP-LINE DATA IS EXPECTED IN FIRST HALF OF 2026 Source text: ID:nBw6Gpn6ba Further company coverage: UTHR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug